• 1
    Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995; 80: 24957.
  • 2
    Woulfe DS. Platelet G protein-coupled receptors in hemostasis and thrombosis. J Thromb Haemost 2005; 3: 2193200.
  • 3
    Brass LF, Manning DR, Cichowski K, Abrams CS. Signaling through G Proteins in platelets: to the integrins and beyond. Thromb Haemost 1997; 78: 5819.
  • 4
    Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293304.
  • 5
    Akkerman JW, Van Willigen G. Platelet activation via trimeric GTP-binding proteins. Haemostasis 1996; 26: 199209.
  • 6
    Ferreira P, Meyer I, Mollner S, Frank R, Pfeuffer T. Selective formation of Gsalpha-MHC I complexes after desensitization of human platelets with iloprost. Eur J Biochem 1999; 259: 16774.
  • 7
    Freson K, Hashimoto H, Thys C, Wittevrongel C, Danloy S, Morita Y, Shintani N, Tomiyama Y, Vermylen J, Hoylaerts MF, Baba A, Van Geet C. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J Clin Invest 2004; 113: 90512.
  • 8
    Hung DT, Wong YH, Vu TK, Coughlin SR. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem 1992; 267: 208314.
  • 9
    Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 80704.
  • 10
    Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389: 1836.
  • 11
    Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5: 1199202.
  • 12
    Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999; 104: 17317.
  • 13
    Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 74554.
  • 14
    Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994; 91: 5048.
  • 15
    Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O’Brien PJ, Manning D, Poncz M, Lucki I, Blendy JA, Brass LF. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci USA 2000; 97: 998498.
  • 16
    Sham RL, Francis CW. Evaluation of mild bleeding disorders and easy bruising. Blood Rev 1994; 8: 98104.
  • 17
    Freson K, Peeters K, De Vos R, Wittevrongel C, Thys C, Hoylaerts MF, Vermylen J, Van Geet C. PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications. Blood 2008; 111: 188593.
  • 18
    Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet ‘primary secretion defect’ are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20: 1016.
  • 19
    Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 197883.
  • 20
    Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 16627.
  • 21
    Higuchi W, Fuse I, Hattori A, Aizawa Y. Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity. Thromb Haemost 1999; 82: 152831.
  • 22
    Tamponi G, Pannocchia A, Arduino C, Bazzan M, Della Dora N, Schinco P, Buraglio M, Eandi M. Congenital deficiency of alpha-2-adrenoceptors on human platelets: description of two cases. Thromb Haemost 1987; 58: 101216.
  • 23
    Freson K, Izzi B, Labarque V, Van Helvoirt M, Thys C, Wittevrongel C, Bex M, Bouillon R, Godefroid N, Proesmans W, De Zegher F, Jaeken J, Van Geet C. GNAS defects identified by stimulatory G protein alpha-subunit signaling studies in platelets. J Clin Endocrinol Metab 2008; 93: 48519.
  • 24
    Freson K, Izzi B, Jaeken J, Van Helvoirt M, Thys C, Wittevrongel C, De Zegher F, Van Geet C. Compound heterozygous mutations in the GNAS gene of a boy with morbid obesity, thyroid-stimulating hormone resistance, pseudohypoparathyroidism, and a prothrombotic state. J Clin Endocrinol Metab 2008; 93: 48449.
  • 25
    Freson K, Thys C, Wittevrongel C, Proesmans W, Hoylaerts MF, Vermylen J, Van Geet C. Pseudohypoparathyroidism type Ib with disturbed imprinting in the GNAS1 cluster and Gsalpha deficiency in platelets. Hum Mol Genet 2002; 11: 274150.
  • 26
    Freson K, Hoylaerts MF, Jaeken J, Eyssen M, Arnout J, Vermylen J, Van Geet C. Genetic variation of the extra-large stimulatory G protein alpha-subunit leads to Gs hyperfunction in platelets and is a risk factor for bleeding. Thromb Haemost 2001; 86: 7338.
  • 27
    Freson K, Jaeken J, Van Helvoirt M, De Zegher F, Wittevrongel C, Thys C, Hoylaerts MF, Vermylen J, Van Geet C. Functional polymorphisms in the paternally expressed XLalphas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation. Hum Mol Genet 2003; 12: 112130.
  • 28
    Jaeken JC, Freson K, Goemans NM, De Cock PP, De Vos RM, Lagae LG, Van Geet CA. G protein diseases: newly recognized causes of metabolic encephalopathy. Eur J Paediatr Neurol 2003; 7: 21115.
  • 29
    Offermanns S, Hashimoto K, Watanabe M, Sun W, Kurihara H, Thompson RF, Inoue Y, Kano M, Simon MI. Impaired motor coordination and persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking G-alpha-q. Proc Nat Acad Sci USA 1997; 94: 1408994.
  • 30
    Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N, Rao AK. Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 1997; 94: 87505.
  • 31
    Gabbeta J, Vaidyula VR, Dhanasekaran DN, Rao AK. Human platelet Galphaq deficiency is associated with decreased Galphaq gene expression in platelets but not neutrophils. Thromb Haemost 2002; 87: 12933.
  • 32
    Patel YM, Patel K, Rahman S, Smith MP, Spooner G, Sumathipala R, Mitchell M, Flynn G, Aitken A, Savidge G. Evidence for a role for Galphai1 in mediating weak agonist-induced platelet aggregation in human platelets: reduced Galphai1 expression and defective Gi signaling in the platelets of a patient with a chronic bleeding disorder. Blood 2003; 101: 482835.
  • 33
    Watson N, Linder ME, Druey KM, Kehrl JH, Blumer KJ. RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits. Nature 1996; 383: 1725.
  • 34
    Kim SD, Sung HJ, Park SK, Kim TW, Park SC, Kim SK, Cho JY, Rhee MH. The expression patterns of RGS transcripts in platelets. Platelets 2006; 17: 4937.
  • 35
    Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. RGS2/G0S8 is a selective inhibitor of Gqalpha function. Proc Natl Acad Sci USA 1997; 94: 1438993.
  • 36
    Roy AA, Baragli A, Bernstein LS, Hepler JR, Hebert TE, Chidiac P. RGS2 interacts with Gs and adenylyl cyclase in living cells. Cell Signal 2006; 18: 33648.
  • 37
    Noé L, Freson K, Giets E, Thijs C, Wittevrongel C, Van Geet C. Loss of Gs activity in platelets from carriers with a heterozygous missense mutation in the regulator of G Protein Signaling 2 (RGS2). Blood 2008; 112. abstract 2861.
  • 38
    Lee SB, Rao AK, Lee KH, Yang X, Bae YS, Rhee SG. Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood 1996; 88: 168491.
  • 39
    Mao GF, Vaidyula VR, Kunapuli SP, Rao AK. Lineage-specific defect in gene expression in human platelet phospholipase C-beta2 deficiency. Blood 2002; 99: 90511.
  • 40
    Freson K, Labarque V, Thys C, Wittevrongel C, Geet CV. What’s new in using platelet research? To unravel thrombopathies and other human disorders. Eur J Pediatr 2007; 166: 120310.